<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03766347</url>
  </required_header>
  <id_info>
    <org_study_id>17-005618</org_study_id>
    <nct_id>NCT03766347</nct_id>
  </id_info>
  <brief_title>Pediatric NMOSD Observational Study</brief_title>
  <official_title>Pediatric Neuromyelitis Optica Spectrum Disorder (NMOSD) 1 Year Observational Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Alexion Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being done to develop a database of pediatric patients in order to study the
      cause, early detection and best treatment for neuromyelitis optica spectrum disorder (NMOSD)
      in pediatric patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is being done to collect information on the natural history of NMOSD in pediatric
      AQP4-IgG seropositive patients. A major restriction in performing drug studies in pediatric
      patients with NMOSD is limited information on the course of the disease in these patients.
      Collecting clinical information over the course of a 1 year observational study would inform
      on the natural history of the disease in these patients. A repository of pediatric patients
      with rare diseases can increase knowledge on the natural history of the specific disease,
      assist in identifying appropriate patients fulfilling specified criteria for drug studies and
      potentially serve as a control group.

      Timepoints: Baseline, 3mo, 6mo, 9mo, 12mo (+/- 1 mo for each time point).

      Baseline data:

        -  Demographics [age/sex/ethnicity],

        -  Clinical presentation information including date of initial diagnosis,

        -  Clinical phenotype

        -  Immunotherapy used current and past,

        -  Family history of autoimmune diseases,

        -  Serological data results

        -  Radiologic data as available

      Self-Report Assessments will be:

        -  Current impairment, as measured by the expanded disability status scale (EDSS) score
           self-reported using Ratzker (1997) EDSS Self Report form,

        -  Quality of life as measured by the EQ-5D and Varni's (1998) PedsQL over the
           phone/mail/email.

      At follow-up visits 3mo, 6mo, 9mo, 12mo (+/- 1 mo for each time point):

        -  Attacks/relapses

        -  Any hospitalizations

        -  Confirm medications and update records if changes

      Self-Report Assessments at follow-up will be:

        -  Current impairment, as measured by the EDSS score self-reported using Ratzker (1997)
           EDSS Self Report form,

        -  Quality of life as measured by the EQ-5D and PedsQL over the phone/mail/email.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2018</start_date>
  <completion_date type="Anticipated">February 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>Time to relapse</measure>
    <time_frame>One year.</time_frame>
    <description>Relapse events of NMOSD defined by clinical worsening of neurological symptoms and treatment.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Neuromyelitis Optica</condition>
  <condition>NMO Spectrum Disorder</condition>
  <arm_group>
    <arm_group_label>Pediatric Neuromyelitis Optica</arm_group_label>
    <description>Participants under the age of 18 that are positive for Aquaporin-4 antibody.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Any pediatric patients that have tested positive for AQP4 antibody regardless of geographic
        location.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  AQP4 positive

          -  Ability to give informed consent by patient or caregiver

        Exclusion Criteria:

        - Inability to complete required forms via phone, mail, or email.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sean J Pittock, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cara L Thomas, AA</last_name>
    <phone>507-422-5563</phone>
    <email>thomas.cara@mayo.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Katie Dunlay, BA</last_name>
    <phone>507-538-5418</phone>
    <email>dunlay.katie@mayo.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sean J. Pittock, M.D.</last_name>
      <phone>507-266-3196</phone>
      <email>pittock.sean@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Sean J. Pittock, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>December 4, 2018</study_first_submitted>
  <study_first_submitted_qc>December 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 6, 2018</study_first_posted>
  <last_update_submitted>June 10, 2020</last_update_submitted>
  <last_update_submitted_qc>June 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Sean Pittock</investigator_full_name>
    <investigator_title>Prinicpal Investigator</investigator_title>
  </responsible_party>
  <keyword>Pediatric</keyword>
  <keyword>Aquaporin-4</keyword>
  <keyword>AQP4</keyword>
  <keyword>NMOSD</keyword>
  <keyword>NMO</keyword>
  <keyword>Neuromyelitis Optica</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuromyelitis Optica</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

